{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:51:32Z","timestamp":1792086692447,"version":"4.4.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"DOI":"10.1007\/s00261-025-05367-z","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:57:51Z","timestamp":1778039871000},"page":"5385-5401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent developments and prospects in locoregional therapy of hepatocellular carcinoma"],"prefix":"10.1007","volume":"51","author":[{"given":"Lauren","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirudh","family":"Maddali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Madoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooman","family":"Yarmohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil I.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Kokabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Georgiades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armeen","family":"Mahvash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiman","family":"Habibollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nariman","family":"Nezami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"5367_CR1","doi-asserted-by":"publisher","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021\/05\/01;71(3). https:\/\/doi.org\/10.3322\/caac.21660.","DOI":"10.3322\/caac.21660"},{"key":"5367_CR2","doi-asserted-by":"publisher","unstructured":"Rumgay H, Ferlay J, Martel Cd, Georges D, Ibrahim AS, Zheng R, et al. Global, regional and national burden of primary liver cancer by subtype. European Journal of Cancer. 2022\/01\/01;161.  https:\/\/doi.org\/10.1016\/j.ejca.2021.11.023.","DOI":"10.1016\/j.ejca.2021.11.023"},{"key":"5367_CR3","doi-asserted-by":"publisher","unstructured":"Chen TC, Hsu SW, Chen YY, Yang HH, Su WW, Hsu YC, et al. Increased prevalence but decreased survival of nonviral hepatocellular carcinoma compared to viral hepatocellular carcinoma in recent ten years. Sci Rep. 2024;14(1). https:\/\/doi.org\/10.1038\/s41598-024-59668-2.","DOI":"10.1038\/s41598-024-59668-2"},{"key":"5367_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.10.020","author":"M Reig","year":"2025","unstructured":"Reig M, Sanduzzi-Zamparelli M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, et al. BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update. J Hepatol. 2025.  https:\/\/doi.org\/10.1016\/j.jhep.2025.10.020.","journal-title":"J Hepatol"},{"key":"5367_CR5","doi-asserted-by":"publisher","unstructured":"Patel KR, Menon H, Patel RR, Huang EP, Verma V, Escorcia FE. Locoregional Therapies for Hepatocellular Carcinoma. JAMA Network Open. 2024\/11\/04;7(11). https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.47995.","DOI":"10.1001\/jamanetworkopen.2024.47995"},{"key":"5367_CR6","doi-asserted-by":"publisher","unstructured":"Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md). 2023;78(6).  https:\/\/doi.org\/10.1097\/HEP.0000000000000466.","DOI":"10.1097\/HEP.0000000000000466"},{"key":"5367_CR7","doi-asserted-by":"publisher","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology. 2022\/03\/01;76(3).  https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","DOI":"10.1016\/j.jhep.2021.11.018"},{"key":"5367_CR8","doi-asserted-by":"publisher","unstructured":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma - PubMed. Journal of hepatology. 2025;82(2). https:\/\/doi.org\/10.1016\/j.jhep.2024.08.028.","DOI":"10.1016\/j.jhep.2024.08.028"},{"key":"5367_CR9","doi-asserted-by":"publisher","unstructured":"GBD 2019 Hepatocellular Carcinoma Collaborators. Global, regional, and national burden of primary liver cancer and its etiologies, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;399(10331):1345\u20131362. https:\/\/doi.org\/10.1016\/S0140-6736(22)01200-4.","DOI":"10.1016\/S0140-6736(22)01200-4"},{"issue":"5","key":"5367_CR10","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable hepatocellular carcinoma: the LEGACY study. Hepatology. 2021;74(5):2342\u20132352. https:\/\/doi.org\/10.1002\/hep.31819.","journal-title":"Hepatology"},{"issue":"10","key":"5367_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00270-022-03215-x","volume":"33","author":"RN Srinivasa","year":"2022","unstructured":"Srinivasa RN, Yarmohammadi H, Maybody M, Erinjeri JP, Brown KT, Covey AM, et al. Management of hepatocellular carcinoma with locoregional therapies: update from the Society of Interventional Radiology consensus conference. J Vasc Interv Radiol. 2022;33(10):1215\u20131230. https:\/\/doi.org\/10.1007\/s00270-022-03215-x.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"5367_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17\u201329. https:\/\/doi.org\/10.1016\/S2468-1253(20)30290-9","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5367_CR13","doi-asserted-by":"publisher","unstructured":"Gabr A, Riaz A, Johnson GE, Kim E, Padia S, Lewandowski RJ, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. European Journal of Nuclear Medicine and Molecular Imaging 2020 48:2. 2020-08-04;48(2). https:\/\/doi.org\/10.1007\/s00259-020-04976-8.","DOI":"10.1007\/s00259-020-04976-8"},{"issue":"2","key":"5367_CR14","doi-asserted-by":"publisher","DOI":"10.1053\/j.tvir.2019.02.011","volume":"22","author":"DM Biederman","year":"2019","unstructured":"Biederman DM, Titano JJ. Y90 radioembolization dosimetry: concepts for the interventional radiologist. Tech Vasc Interv Radiol. 2019;22(2):100635. https:\/\/doi.org\/10.1053\/j.tvir.2019.02.011","journal-title":"Tech Vasc Interv Radiol"},{"key":"5367_CR15","doi-asserted-by":"publisher","unstructured":"Mahvash A, Chartier S, Turco M, Habib P, Griffith S, Brown S, et al. A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study. BMC Gastroenterology. 2022;22(1).  https:\/\/doi.org\/10.1186\/s12876-022-02204-1.","DOI":"10.1186\/s12876-022-02204-1"},{"key":"5367_CR16","unstructured":"Kappadath C, Sarwar A, Nadolski G, Kokabi N, Wehrenberg-Klee E. DOORwaY90: Selective Internal Radiation Therapy using SIR-Spheres Y-90 Resin Microspheres as first-line treatment for unresectable Hepatocellular Carcinoma patients \u2013 an interim analysis. CIRSE. Barcelona, Spain2025."},{"issue":"1","key":"5367_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1148\/radiol.2019182326","volume":"292","author":"JP Eisenhauer","year":"2019","unstructured":"Eisenhauer JP, Farris GC, Anderson GJ, Ahmed M, Clark J, de Baere T et al. Immunotherapy and the interventional oncologist: challenges and opportunities\u2014a Society of Interventional Oncology white paper. Radiology. 2019;292(1):1\u201310. https:\/\/doi.org\/10.1148\/radiol.2019182326","journal-title":"Radiology"},{"key":"5367_CR18","doi-asserted-by":"publisher","unstructured":"GBD 2021 Liver Cancer Collaborators. The global, regional, and national burden of liver cancer and its risk factors from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10411):1036\u20131055. https:\/\/doi.org\/10.1016\/S0140-6736(23)01796-8.","DOI":"10.1016\/S0140-6736(23)01796-8"},{"issue":"9","key":"5367_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003311","volume":"9","author":"DJ Pinato","year":"2021","unstructured":"Pinato DJ, Marinaki S, Farid J, Tovoli F, Ferla P, Tsochatzis P et al. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer. 2021;9(9):e003311. https:\/\/doi.org\/10.1136\/jitc-2021-003311","journal-title":"J Immunother Cancer"},{"key":"5367_CR20","doi-asserted-by":"publisher","unstructured":"Bourcier S, Kelley RK, Eisenhauer EA, Qin S, Rizzo Z, Cheng AL, et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2025;405(10474). https:\/\/doi.org\/10.1016\/S0140-6736(24)02551-0.","DOI":"10.1016\/S0140-6736(24)02551-0"},{"key":"5367_CR21","doi-asserted-by":"publisher","unstructured":"Kelley RK, Qin S, Gyawali Y, Han G, Llovet JM, Zhu J, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2025;405(10474). https:\/\/doi.org\/10.1016\/S0140-6736(24)02575-3.","DOI":"10.1016\/S0140-6736(24)02575-3"},{"key":"5367_CR22","unstructured":"Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma. https:\/\/www.merck.com\/news\/merck-and-eisai-provide-update-on-phase-3-leap-012-trial-in-unresectable-non-metastatic-hepatocellular-carcinoma\/ (2025). Accessed 11\/03\/2025 2025."},{"key":"5367_CR23","doi-asserted-by":"publisher","unstructured":"Pinato DJ, D\u2019Alessio A, Fulgenzi CAM, Schlaak AE, Celsa C, Killmer S, et al. Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study. Clinical Cancer Research. 2024;30(11). https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0177.","DOI":"10.1158\/1078-0432.CCR-24-0177"},{"key":"5367_CR24","doi-asserted-by":"publisher","unstructured":"Rivoltini L, Bhoori S, Camisaschi C, Bergamaschi L, Lalli L, Frati P, et al. Y90-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers. Gut. 2023-02-01;72(2).  https:\/\/doi.org\/10.1136\/gutjnl-2021-326869.","DOI":"10.1136\/gutjnl-2021-326869"},{"key":"5367_CR25","doi-asserted-by":"publisher","unstructured":"He AR, Toskich B. The ROWAN study: Safety and efficacy of transarterial radioembolization with Y-90 glass microspheres and the STRIDE regimen in hepatocellular carcinoma. Journal of Clinical Oncology. 2023-2-1;41(4_suppl). https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.TPS622.","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS622"},{"key":"5367_CR26","doi-asserted-by":"publisher","unstructured":"Salem R, Greten TF. Interventional radiology meets immuno-oncology for hepatocellular carcinoma. Journal of Hepatology. 2024\/06\/01;80(6). https:\/\/doi.org\/10.1016\/j.jhep.2022.08.003.","DOI":"10.1016\/j.jhep.2022.08.003"},{"key":"5367_CR27","doi-asserted-by":"publisher","unstructured":"Chung JW. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in the Era of New Systemic Agents. Radiology. 2022-02-01;303(2).  https:\/\/doi.org\/10.1148\/radiol.212826.","DOI":"10.1148\/radiol.212826"},{"issue":"2","key":"5367_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.21.00608","volume":"40","author":"QJ Lyu","year":"2022","unstructured":"Lyu QJ, He MK, Chen HW, Fan WQ, Zhou YM, Xu L et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol. 2022;40(2):150\u2013160. https:\/\/doi.org\/10.1200\/JCO.21.00608","journal-title":"J Clin Oncol"},{"issue":"3","key":"5367_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00280-018-3638-0","volume":"82","author":"JH Choi","year":"2018","unstructured":"Choi JH, Choi WJ, Bae SH, Sung DS, Shim MJ, Kim YS et al.  Randomized, prospective, comparative study on the effects and safety of sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2018;82(3):403\u2013411. https:\/\/doi.org\/10.1007\/s00280-018-3638-0","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"5367_CR30","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00262-016-1837-2","volume":"65","author":"T Yamamoto","year":"2016","unstructured":"Yamamoto T, Kudo A, Takahashi T, Matsui K, Nakamura H et al. Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Immunol Immunother. 2016;65(6):733\u2013743. https:\/\/doi.org\/10.1007\/s00262-016-1837-2","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"5367_CR31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1148\/radiol.211545","volume":"303","author":"K Zhang","year":"2022","unstructured":"Zhang K, Zhang X, Fan S, Chen G, Liu WQ, Xu L et al. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial. Radiology. 2022;303(2):322\u2013331. https:\/\/doi.org\/10.1148\/radiol.211545","journal-title":"Radiology"},{"issue":"6","key":"5367_CR32","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S2468-1253(18)30078-5","volume":"3","author":"M Kudo","year":"2018","unstructured":"Kudo M, Ueshima K, Ohkawa Y, Ogasawara S, Otsuka S, Ikeda N et al.  Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open-label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):424\u2013432. https:\/\/doi.org\/10.1016\/S2468-1253(18)30078-5","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5367_CR33","doi-asserted-by":"publisher","unstructured":"Gao W, Pan Z-L, Zhao X-H, Yang L, Cao J-B, Li D-Y, et al. Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study). eClinicalMedicine. 2025\/05\/01;83.  https:\/\/doi.org\/10.1016\/j.eclinm.2025.103217.","DOI":"10.1016\/j.eclinm.2025.103217"},{"key":"5367_CR34","doi-asserted-by":"publisher","unstructured":"Zhou Z, Zheng Z, He M, Zhang Y, Pan Y, Liu Z, et al. Hepatic arterial infusion chemotherapy combined with donafenib and tislelizumab versus transcatheter chemoembolization alone for hepatocellular carcinoma: A propensity score matching study. Journal of Clinical Oncology. 2025-6-1;43(16_suppl). https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4094.","DOI":"10.1200\/JCO.2025.43.16_suppl.4094"},{"issue":"6","key":"5367_CR35","doi-asserted-by":"publisher","first-page":"e815","DOI":"10.1097\/SLA.0000000000005434","volume":"276","author":"MH Squires","year":"2022","unstructured":"Squires MH, Chaudry M, Wachtel H, Kooby DA, Ueno H, Hochwald SN et al. Hepatic artery infusion pumps: a surgical toolkit for intraoperative decision-making and management of hepatic artery infusion-specific complications. Ann Surg. 2022;276(6):e815\u2013e823. https:\/\/doi.org\/10.1097\/SLA.0000000000005434","journal-title":"Ann Surg"},{"key":"5367_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/chem.202400000","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhang Y, Li G. Advanced microsphere and hydrogel platforms for precision interventional therapy of hepatocellular carcinoma. Chemistry 2024. https:\/\/doi.org\/10.1002\/chem.202400000","journal-title":"Chemistry"},{"key":"5367_CR37","doi-asserted-by":"publisher","unstructured":"Ganguli S, Lareau R, Jarrett T, Soulen MC. A Water-Based Liquid Embolic: Evaluation of its Safety and Efficacy in a Rabbit Kidney Model. Journal of Vascular and Interventional Radiology. 2021\/06\/01;32(6).  https:\/\/doi.org\/10.1016\/j.jvir.2021.02.018.","DOI":"10.1016\/j.jvir.2021.02.018"},{"key":"5367_CR38","doi-asserted-by":"publisher","unstructured":"Goh GS, Goodwin MD, Huang J-F, Kavnoudias H, Holden A. A Pilot First-in-Human Study of Embrace, a Polyethylene Glycol-Based Liquid Embolic Agent, in the Embolization of Malignant and Benign Hypervascular Tumors. Journal of Vascular and Interventional Radiology. 2022\/06\/01;33(6).  https:\/\/doi.org\/10.1016\/j.jvir.2022.02.021.","DOI":"10.1016\/j.jvir.2022.02.021"},{"key":"5367_CR39","doi-asserted-by":"publisher","unstructured":"Abi-Jaoudeh N, Chen J, Dey C, Tahour D, Novelli P, Charalel R, et al. Abstract No. LBA9 The Instylla HES Hypervascular Tumor Study: A Prospective, Randomized, Multicenter Study of a Liquid Embolic for Treatment of Hypervascular Tumors. Journal of Vascular and Interventional Radiology. 2025\/03\/01;36(3). https:\/\/doi.org\/10.1016\/j.jvir.2025.01.017.","DOI":"10.1016\/j.jvir.2025.01.017"},{"key":"5367_CR40","doi-asserted-by":"publisher","unstructured":"Pe J, Choi B, Choi H, Kwon SW, Kim D-H, Pe J, et al. Preclinical Therapeutic Evaluation of Lenvatinib-Eluting Microspheres for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma. CardioVascular and Interventional Radiology 2022 45:12. 2022-08-12;45(12). https:\/\/doi.org\/10.1007\/s00270-022-03242-8.","DOI":"10.1007\/s00270-022-03242-8"},{"key":"5367_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202400000","author":"H Kim","year":"2024","unstructured":"Kim H, Choi B, Moon SK, Choi H, Han KR, Kim LM et al. Preclinical development and validation of translational temperature-sensitive iodized oil emulsion-mediated transcatheter arterial chemo-immuno-embolization for the treatment of hepatocellular carcinoma. Adv Healthc Mater 2024. https:\/\/doi.org\/10.1002\/adhm.202400000","journal-title":"Adv Healthc Mater"},{"key":"5367_CR42","doi-asserted-by":"publisher","unstructured":"Valery M, Cervantes B, Samaha R, Gelli M, Smolenschi C, Fuerea A, et al. Immunotherapy and Hepatocellular Cancer: Where Are We Now? Cancers. 2022;14(18). https:\/\/doi.org\/10.3390\/cancers14184523.","DOI":"10.3390\/cancers14184523"},{"key":"5367_CR43","doi-asserted-by":"publisher","unstructured":"Stella M, Braat AJAT, Rooij Rv, Jong HWAMd, Lam MGEH. Holmium-166 Radioembolization: Current Status and Future Prospective. Cardiovascular and Interventional Radiology. 2022;45(11).  https:\/\/doi.org\/10.1007\/s00270-022-03187-y.","DOI":"10.1007\/s00270-022-03187-y"},{"key":"5367_CR44","doi-asserted-by":"publisher","unstructured":"Abraham RJ, Arepally A, Liu D, Lewandowski R, Kappadath SC, Verma A, et al. Imageable Radioembolization Microspheres for Treatment of Unresectable Hepatocellular Carcinoma: Interim Results from a First-in-Human Trial. Journal of Vascular and Interventional Radiology. 2024\/10\/01;35(10). https:\/\/doi.org\/10.1016\/j.jvir.2024.06.023.","DOI":"10.1016\/j.jvir.2024.06.023"},{"key":"5367_CR45","doi-asserted-by":"publisher","unstructured":"Reinders MTM, Braat AJAT, van Erpecum KJ, de Bruijne J, Bruijnen RCG, Sprengers D, et al. Holmium-166 radioembolisation dosimetry in HCC. European Journal of Nuclear Medicine and Molecular Imaging 2024 52:3. 2024-10-29;52(3). https:\/\/doi.org\/10.1007\/s00259-024-06940-2.","DOI":"10.1007\/s00259-024-06940-2"},{"issue":"5","key":"5367_CR46","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.jvir.2016.12.1221","volume":"28","author":"SA Padia","year":"2017","unstructured":"Padia SA, Miller MT, Shah SP, Lee TY, Ahrar V, Madoff TM et al. Correlation of technetium-99m macroaggregated albumin and yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: a retrospective review of pretreatment singlephoton emission CT and posttreatment positron emission tomography\/CT. J Vasc Interv Radiol. 2017;28(5):698\u2013705.e1. https:\/\/doi.org\/10.1016\/j.jvir.2016.12.1221","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"5367_CR47","doi-asserted-by":"publisher","first-page":"492","DOI":"10.2967\/jnumed.112.109819","volume":"54","author":"M Wong","year":"2013","unstructured":"Wong M, Smits ML, Elschot M, de Jong HW, van Vliet HP, van den Bosch MA et al. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. J Nucl Med. 2013;54(3):492\u2013499. https:\/\/doi.org\/10.2967\/jnumed.112.109819","journal-title":"J Nucl Med"},{"key":"5367_CR48","doi-asserted-by":"publisher","unstructured":"Weber M, Lam M, Chiesa C, Konijnenberg M, Cremonesi M, Flamen P, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. European Journal of Nuclear Medicine and Molecular Imaging 2022 49:5. 2022-02-11;49(5).  https:\/\/doi.org\/10.1007\/s00259-021-05600-z.","DOI":"10.1007\/s00259-021-05600-z"},{"key":"5367_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1404621","author":"V Schulze-Zachau","year":"2024","unstructured":"Schulze-Zachau V, Verset G, De Bondt P, De Keukeleire K, G\u00fchne F, Heuschkel M, et al. Frontiers | Safety and efficacy of Holmium-166 selective internal radiotherapy of primary and secondary liver cancer confirmed by real-world data. Frontiers in Oncology. 2024\/06\/11;14.  https:\/\/doi.org\/10.3389\/fonc.2024.1404621.","journal-title":"Frontiers in Oncology"},{"key":"5367_CR50","doi-asserted-by":"publisher","unstructured":"Doyle A, Gorgen A, Muaddi H, Aravinthan AD, Issachar A, Mironov O, et al. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3\u00a0cm in potentially transplantable patients. Journal of Hepatology. 2019\/05\/01;70(5).  https:\/\/doi.org\/10.1016\/j.jhep.2018.12.027.","DOI":"10.1016\/j.jhep.2018.12.027"},{"key":"5367_CR51","doi-asserted-by":"publisher","unstructured":"Kawaguchi Y, Hasegawa K, Kashiwabara K, Okamura Y, Kurosaki M, Kudo M, et al. Surgery Versus Ablation for Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF-RCT Trial) and a Nonrandomized Prospective Observational Trial (SURF-Cohort Trial). Journal of Clinical Oncology. 2025-8-10;43(23). https:\/\/doi.org\/10.1200\/JCO-24-02030.","DOI":"10.1200\/JCO-24-02030"},{"issue":"2","key":"5367_CR52","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jhep.2016.09.003","volume":"66","author":"SJ Ahn","year":"2017","unstructured":"Ahn SJ, Lee JM, Lee DH, Lee SM, Yun JH, Kim YJ et al. Real-time US-CT\/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. J Hepatol. 2017;66(2):347\u2013354. https:\/\/doi.org\/10.1016\/j.jhep.2016.09.003","journal-title":"J Hepatol"},{"key":"5367_CR53","doi-asserted-by":"publisher","unstructured":"Evans M, Kang S, Bajaber A, Gordon K, Charles Martin I. Augmented Reality for Surgical Navigation: A Review of Advanced Needle Guidance Systems for Percutaneous Tumor Ablation. Radiology: Imaging Cancer. 2025;7(1). https:\/\/doi.org\/10.1148\/rycan.230154.","DOI":"10.1148\/rycan.230154"},{"issue":"9","key":"5367_CR54","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1177\/02841851231187638","volume":"64","author":"Y Shen","year":"2023","unstructured":"Shen Y, Sun X, Shi H, Qin J, Li H, Liu J et al.  Fusion imaging versus ultrasoundguided percutaneous thermal ablation of liver cancer: a meta-analysis. Acta Radiol. 2023;64(9):1256\u20131266. https:\/\/doi.org\/10.1177\/02841851231187638","journal-title":"Acta Radiol"},{"key":"5367_CR55","doi-asserted-by":"publisher","unstructured":"Sato M, Tateishi R, Zohar Y, Sato J, Watadani T, Moriyama M, et al. Retrospective evaluation of a novel ultrasound-based imaging analysis software for predicting radiofrequency ablation areas. PLOS ONE. Jan 17, 2025;20(1). https:\/\/doi.org\/10.1371\/journal.pone.0317469.","DOI":"10.1371\/journal.pone.0317469"},{"key":"5367_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2024.111482","author":"S Bodard","year":"2024","unstructured":"Bodard S, Guinebert S, Tacher V, Cornelis FH. The Emergence of robotics in liver interventional radiology: Navigating New Frontiers. European Journal of Radiology. 2024\/06\/01;175. https:\/\/doi.org\/10.1016\/j.ejrad.2024.111482.","journal-title":"European Journal of Radiology"},{"key":"5367_CR57","doi-asserted-by":"publisher","unstructured":"Bodard S, Guinebert S, N. Petre E, Marinelli B, Sarkar D, Barral M, et al. Percutaneous liver interventions with robotic systems: a systematic review of available clinical solutions. British Journal of Radiology. 2023\/12\/01;96(1152).  https:\/\/doi.org\/10.1259\/bjr.20230620.","DOI":"10.1259\/bjr.20230620"},{"key":"5367_CR58","doi-asserted-by":"publisher","unstructured":"Bonnet B, Ba\u00e8re Td, Beunon P, Feddal A, Tselikas L, Deschamps F. Robotic-assisted CT-guided percutaneous thermal ablation of abdominal tumors: An analysis of 41 patients. Diagnostic and Interventional Imaging. 2024\/06\/01;105(6). https:\/\/doi.org\/10.1016\/j.diii.2024.01.005.","DOI":"10.1016\/j.diii.2024.01.005"},{"issue":"4","key":"5367_CR59","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.1016\/S2468-1253(24)00247-4","volume":"10","author":"BY Zhou","year":"2025","unstructured":"Zhou BY, Feng W, Gao JJ, Peng Z, Jin Z, Huang J et al. Combination locoregional and systemic therapies in hepatocellular carcinoma. Lancet Gastroenterol Hepatol. 2025;10(4):e300\u2013e310. https:\/\/doi.org\/10.1016\/S2468-1253(24)00247-4","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5367_CR60","doi-asserted-by":"publisher","unstructured":"LGPH V, EN P, FH C, SB S, G S. Irreversible electroporation and thermal ablation of tumors in the liver, lung, kidney and bone: What are the differences? - PubMed. Diagnostic and interventional imaging. 2017;98(9).  https:\/\/doi.org\/10.1016\/j.diii.2017.07.007.","DOI":"10.1016\/j.diii.2017.07.007"},{"key":"5367_CR61","doi-asserted-by":"publisher","unstructured":"Rhim H, Lim HK. Radiofrequency Ablation of Hepatocellular Carcinoma: Pros and Cons. Gut and Liver. 2010;4(Suppl 1).  https:\/\/doi.org\/10.5009\/gnl.2010.4.S1.S113.","DOI":"10.5009\/gnl.2010.4.S1.S113"},{"key":"5367_CR62","doi-asserted-by":"publisher","unstructured":"Yun JH, Fang A, Khorshidi F, Habibollahi P, Kutsenko O, Etezadi V, et al. New Developments in Image-Guided Percutaneous Irreversible Electroporation of Solid Tumors. Current Oncology Reports 2023 25:11. 2023-09-11;25(11). https:\/\/doi.org\/10.1007\/s11912-023-01452-y.","DOI":"10.1007\/s11912-023-01452-y"},{"key":"5367_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.811726","author":"N Zhang","year":"2022","unstructured":"Zhang N, Li Z, Han X, Zhu Z, Li Z, Zhao Y, et al. Frontiers | Irreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors. Frontiers in Immunology. 2022\/01\/07;12.  https:\/\/doi.org\/10.3389\/fimmu.2021.811726.","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"5367_CR64","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/cancers15030732","volume":"15","author":"T Wada","year":"2023","unstructured":"Wada T, Saito K, Sato K, Takahashi H, Kimura T, Tanaka Y et al. Comparisons of radiofrequency ablation, microwave ablation, and irreversible electroporation by using propensity score analysis for early-stage hepatocellular carcinoma. Cancers (Basel). 2023;15(3):732. https:\/\/doi.org\/10.3390\/cancers15030732","journal-title":"Cancers (Basel)"},{"issue":"1","key":"5367_CR65","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1148\/radiol.2016151243","volume":"280","author":"TH Kim","year":"2016","unstructured":"Kim TH, Lee HK, Lee MW, Kim YS, Rhim H, Lim WJ et al.  Long-term therapeutic outcomes of radiofrequency ablation for subcapsular versus nonsubcapsular hepatocellular carcinoma: a propensity score matched study. Radiology. 2016;280(1):262\u2013271. https:\/\/doi.org\/10.1148\/radiol.2016151243","journal-title":"Radiology"},{"issue":"3","key":"5367_CR66","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s00270-019-02394-4","volume":"43","author":"SY Cho","year":"2020","unstructured":"Cho SY, Kim TH, Moon JH, Song KD, Lee MW, Rhim H et al. RF ablation versus cryoablation for small perivascular hepatocellular carcinoma: propensity score analyses of mid-term outcomes. Cardiovasc Intervent Radiol. 2020;43(3):384\u2013393. https:\/\/doi.org\/10.1007\/s00270-019-02394-4","journal-title":"Cardiovasc Intervent Radiol"},{"key":"5367_CR67","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-025-12044-8","author":"M Xu","year":"2025","unstructured":"Xu M, Yang S, Zhang Q, Tan G, Peng J, Deng G et al. Recurrence patterns and survival outcomes after irreversible electroporation for hepatocellular carcinoma: a 6-year multicenter experience. Eur Radiol 2025. https:\/\/doi.org\/10.1007\/s00330-025-12044-8","journal-title":"Eur Radiol"},{"key":"5367_CR68","doi-asserted-by":"publisher","unstructured":"Kim DH, Suh RD, Chiang J, Abtin F, Genshaft SJ, Hao F, et al. Technical Feasibility and Safety of Image-Guided Biphasic Monopolar Pulsed Electric Field Ablation of Metastatic and Primary Malignancies. Journal of Vascular and Interventional Radiology. 2024\/11\/01;35(11).  https:\/\/doi.org\/10.1016\/j.jvir.2024.08.003.","DOI":"10.1016\/j.jvir.2024.08.003"},{"issue":"5","key":"5367_CR69","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002361","volume":"111","author":"M Xu","year":"2025","unstructured":"Xu M, Wang Z, Ding X, Guo D, Zhang R, Tan A et al.  Nanosecond pulsed electric field ablation as first-line curative therapy for hepatocellular carcinoma in high-risk locations: a prospective multicenter study. Int J Surg. 2025;111(5):e2361. https:\/\/doi.org\/10.1097\/JS9.0000000000002361","journal-title":"Int J Surg"},{"key":"5367_CR70","doi-asserted-by":"publisher","unstructured":"Rouhezamin MR, Fintelmann FJ, Huang AJ, Arellano RS, Smolinski-Zhao S, Patel DM, et al. Limited Effectiveness in Early Human Clinical Experience with Pulsed Electrical Field Ablation. Journal of Vascular and Interventional Radiology. 2025\/02\/01;36(2). https:\/\/doi.org\/10.1016\/j.jvir.2024.10.033.","DOI":"10.1016\/j.jvir.2024.10.033"},{"key":"5367_CR71","doi-asserted-by":"publisher","unstructured":"Mir LM, Orlowski S. Mechanisms of electrochemotherapy - PubMed. Advanced drug delivery reviews. 01\/04\/1999;35(1). https:\/\/doi.org\/10.1016\/s0169-409x(98)00066-0.","DOI":"10.1016\/s0169-409x(98)00066-0"},{"key":"5367_CR72","doi-asserted-by":"publisher","unstructured":"Geboers B, Scheffer HJ, Graybill PM, Ruarus AH, Nieuwenhuizen S, Puijk RS, et al. High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy. Radiology. 2020-03-24;295(2). https:\/\/doi.org\/10.1148\/radiol.2020192190.","DOI":"10.1148\/radiol.2020192190"},{"key":"5367_CR73","doi-asserted-by":"publisher","unstructured":"Campana LG, Miklav\u010di\u010d D, Bertino G, Marconato R, Valpione S, Imarisio I, et al. Electrochemotherapy of superficial tumors \u2013 Current status:: Basic principles, operating procedures, shared indications, and emerging applications. Seminars in Oncology. 2019\/04\/01;46(2).  https:\/\/doi.org\/10.1053\/j.seminoncol.2019.04.002.","DOI":"10.1053\/j.seminoncol.2019.04.002"},{"key":"5367_CR74","doi-asserted-by":"publisher","unstructured":"Calvet CY, Mir LM, Calvet CY, Mir LM. The promising alliance of anti-cancer electrochemotherapy with immunotherapy. Cancer and Metastasis Reviews 2016 35:2. 2016-03-18;35(2).  https:\/\/doi.org\/10.1007\/s10555-016-9615-3.","DOI":"10.1007\/s10555-016-9615-3"},{"key":"5367_CR75","doi-asserted-by":"publisher","unstructured":"Edhemovic I, Brecelj E, Gasljevic G, Music MM, Gorjup V, Mali B, et al. Intraoperative electrochemotherapy of colorectal liver metastases. Journal of Surgical Oncology. 2014\/09\/01;110(3).  https:\/\/doi.org\/10.1002\/jso.23625.","DOI":"10.1002\/jso.23625"},{"key":"5367_CR76","doi-asserted-by":"publisher","unstructured":"Djokic M, Cemazar M, Popovic P, Kos B, Dezman R, Bosnjak M, et al. Electrochemotherapy as treatment option for hepatocellular carcinoma, a prospective pilot study. European Journal of Surgical Oncology. 2018\/05\/01;44(5).  https:\/\/doi.org\/10.1016\/j.ejso.2018.01.090.","DOI":"10.1016\/j.ejso.2018.01.090"},{"key":"5367_CR77","doi-asserted-by":"publisher","unstructured":"Izadifar Z, Izadifar Z, Chapman D, Babyn P, Izadifar Z, Izadifar Z, et al. An Introduction to High Intensity Focused Ultrasound: Systematic Review on Principles, Devices, and Clinical Applications. Journal of Clinical Medicine 2020, Vol 9, Page 460. 2020-02-07;9(2).  https:\/\/doi.org\/10.3390\/jcm9020460.","DOI":"10.3390\/jcm9020460"},{"key":"5367_CR78","doi-asserted-by":"publisher","unstructured":"Bachu VS, Kedda J, Suk I, Green JJ, Tyler B, Bachu VS, et al. High-Intensity Focused Ultrasound: A Review of Mechanisms and Clinical Applications. Annals of Biomedical Engineering 2021 49:9. 2021-08-10;49(9). https:\/\/doi.org\/10.1007\/s10439-021-02833-9.","DOI":"10.1007\/s10439-021-02833-9"},{"key":"5367_CR79","doi-asserted-by":"publisher","unstructured":"Zhou Y-F. High intensity focused ultrasound in clinical tumor ablation. http:\/\/wwwwjgnetcom\/. Jan 10, 2011;2(1).  https:\/\/doi.org\/10.5306\/wjco.v2.i1.8.","DOI":"10.5306\/wjco.v2.i1.8"},{"key":"5367_CR80","doi-asserted-by":"publisher","unstructured":"Elhelf IAS, Albahar H, Shah U, Oto A, Cressman E, Almekkawy M. High intensity focused ultrasound: The fundamentals, clinical applications and research trends. Diagnostic and Interventional Imaging. 2018\/06\/01;99(6).  https:\/\/doi.org\/10.1016\/j.diii.2018.03.001.","DOI":"10.1016\/j.diii.2018.03.001"},{"issue":"1","key":"5367_CR81","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/02656736.2021.1905189","volume":"38","author":"Z Xu","year":"2021","unstructured":"Xu Z, Hwang TL, Vlaisavljevich E, Laeseke PF. Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound. Int J Hyperthermia. 2021;38(1):561\u2013575. https:\/\/doi.org\/10.1080\/02656736.2021.1905189","journal-title":"Int J Hyperthermia"},{"key":"5367_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultras.2017.11.012","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Wang X. Effect of pulse duration and pulse repetition frequency of cavitation histotripsy on erosion at the surface of soft material. Ultrasonics. 2018\/03\/01;84.  https:\/\/doi.org\/10.1016\/j.ultras.2017.11.012.","journal-title":"Ultrasonics"},{"key":"5367_CR83","doi-asserted-by":"publisher","unstructured":"Mendiratta-Lala M, Wiggermann P, Pech M, Serres-Cr\u00e9ixams X, White SB, Davis C, et al. The #HOPE4LIVER Single-Arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors. Radiology. 2024-09-03;312(3). https:\/\/doi.org\/10.1148\/radiol.233051.","DOI":"10.1148\/radiol.233051"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-025-05367-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-025-05367-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-025-05367-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:34:45Z","timestamp":1792085685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-025-05367-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":83,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["5367"],"URL":"https:\/\/doi.org\/10.1007\/s00261-025-05367-z","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}